TABLE 2.
Adverse event incidence, frequency, and severity for each study group
| AE measure | Flexyn2a (n = 12) | Flexyn2a + alum (n = 12) | Placebo (n = 6)a |
|---|---|---|---|
| Overall AE incidence, no. (%) | 9 (75) | 10 (83) | 6 (100) |
| Frequency of AEs | 37 | 37 | 24 |
| Severity, no (%) | |||
| Mild | 31 (84) | 29 (78) | 22 (92) |
| Not related | 19 (51) | 14 (38) | 18 (75) |
| Related | 12 (33) | 15 (40) | 4 (17) |
| Moderate | 3 (8) | 7 (19) | 1 (4) |
| Not related | 3 (8) | 5 (14) | 1 (4) |
| Related | 2 (5) | ||
| Severe | 3 (8) | 1 (3) | 1 (4) |
| Not related | 3 (8) | 1 (3) | 1 (4) |
| Related |
a
One subject received only the first injection.